Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT01670877
Title Neratinib +/- Fulvestrant in Metastatic HER2 Non-amplified But HER2 Mutant Breast Cancer
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Washington University School of Medicine
Indications

Her2-receptor negative breast cancer

Therapies

Neratinib

Neratinib + Trastuzumab

Fulvestrant + Neratinib + Trastuzumab

Fulvestrant + Neratinib

Age Groups: adult | senior
Covered Countries USA | CAN


No variant requirements are available.